Literature DB >> 2095351

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.

J W Meyer, B Woggon, P Baumann, U A Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2095351     DOI： 10.1007/bf00316110

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

1.  Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid-chromatography on radially compressed silica.

Authors:  C D Kilts; K S Patrick; G R Breese; R B Mailman
Journal:  J Chromatogr       Date:  1982-09-10

2.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

3.  GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin.

Authors:  P Baumann; M Jonzier-Perey
Journal:  Clin Chim Acta       Date:  1988-02-15       Impact factor: 3.786

4.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

5.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

Authors:  R C Skoda; F J Gonzalez; A Demierre; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

6.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

7.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

8.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962
  8 in total
  11 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.

Authors:  E Spina; M Ancione; A E Di Rosa; M Meduri; A P Caputi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.

Authors:  W A Daniel; M Syrek; A Haduch; J Wójcikowski
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 4.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

5.  Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.

Authors:  An Wang; C David Stout; Qinghai Zhang; Eric F Johnson
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

6.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

7.  Pharmacokinetics of chlorpromazine and key metabolites.

Authors:  P K Yeung; J W Hubbard; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 9.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.